Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 451 to 465 of 670 results for kidney or kidneys or renal

  1. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

    Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.

  2. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

  3. Adrenal insufficiency: identification and management (NG243)

    This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.

  4. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

  5. Gambling-related harms: identification, assessment and management (NG248)

    This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.

  6. Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable (TA1097)

    Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.

  7. Diabetic retinopathy: management and monitoring (NG242)

    This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.

  8. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation (HTG771)

    Evidence-based recommendations on transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation. This involves putting an artificial valve inside the existing faulty valve.

  9. Cryotherapy for renal cancers (IPG207)

    This guidance has been updated and replaced by NICE HealthTech guidance 269 and HealthTech guidance 271.

  10. Key question: caring

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  11. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  12. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)

    Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

  13. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

  14. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  15. Percutaneous cryotherapy for renal cancer (IPG402)

    Interventional procedures, IPG402 - Issued: July 2011 --> We have moved interventional procedures guidance 402 to become HealthTech guidance 269. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.